연구동향 분석

Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study

황희상 김미정 박찬식 윤덕현 서철원 허주령 고현정 년

논문상세정보
인용/피인용

' Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study' 의 참고문헌

  • WHO classification of tumours of haematopoietic and lymphoid tissues
    Swerdlow SH [2017]
  • Validation of the NCCN-IPI for diffuse large B-cell lymphoma(DLBCL) : the addition of beta2-microglobulin yields a more accurate GELTAMO-IPI
    Montalban C [2017]
  • Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older : A Danish population-based cohort study
    Juul MB [2018]
  • The revised International Prognostic Index(R-IPI)is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    Sehn LH [2007]
  • The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age
    Mareschal S [2011]
  • The impact of age on survival of diffuse large B-cell lymphoma : a population-based study
    Hedstrom G [2015]
  • Sites of extranodal involvement are prognostic in patients with diffuse large Bcell lymphoma in the rituximab era : an analysis of the Surveillance, Epidemiology and End Results database
    Castillo JJ [2014]
  • Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease : Cotswolds meeting
    Lister TA [1989]
  • Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis
  • Prognostic significance of actual dose intensity in diffuse large-cell lymphoma : results of a tree-structured survival analysis
    Kwak LW [1990]
  • Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era
    Vaidya R [2014]
  • Pharmacology of antineoplastic medications in older cancer patients
    Balducci L [2009]
  • Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma
    Klapper W [2012]
  • Older age impacts on survival outcome in patients receiving curative surgery for solid cancer
    Lu CH [2018]
  • Martingale-based residuals for survival models
    Therneau TM [1990]
  • Lymphoma in older patients
  • Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte
    Coiffier B [2010]
  • Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma : a nationwide study
    Lyman GH [2004]
  • Improved prognostic stratification using NCCN-and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma
    Hong J [2017]
  • Effect of age on breast cancer patient prognoses : a population-based study using the SEER 18 database
    Chen HL [2016]
  • Diffuse large B-cell lymphoma in Chinese patients : immunophenotypic and cytogenetic analyses of 124 cases
    Chen Y [2010]
  • Diffuse large B-cell lymphoma : 10years’ real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
    Horvat M [2018]
  • Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
    Hans CP [2004]
  • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Coiffier B [2002]
  • Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified
    Hwang HS [2015]
  • An enhanced International Prognostic Index(NCCN-IPI)for patients with diffuse large B-cell lymphoma treated in the rituximab era
    Zhou Z [2014]
  • Age is a prognostic factor affecting survival in lung cancer patients
    Tas F [2013]
  • A predictive model for aggressive non-Hodgkin’s lymphoma